



Contact:
Nancy F. Morter
Dilon Technologies Inc.
C: 757-589-3914
O: 757-269-4910 x 302
E: nfmorter@dilon.com
www.dilon.com

**DILON TECHNOLOGIES LLC: Launches manufacturing & marketing of gamma camera
optimized for diagnostic breast imaging**

(Newport News, VA – March 11, 2004) - Dilon Technologies, LLC is launching full-scale production and sales of its small field-of-view gamma camera optimized for breast imaging. The camera's proven ability to provide clearer and more concise images to women with questionable mammograms is realized after years of cooperative scientific and medical research with the U.S. Department of Energy, several hospitals and major universities. A recent significant capital infusion into the private company allows for the long awaited imaging technology to hit the market.

Breast-Specific Gamma Imaging (BSGI) is a nuclear medicine technique that images the metabolic activity of breast lesions through radiotracer uptake. It is similar to scintimammography, but performed with a high-resolution imaging detector that is optimized for the body region being evaluated. When a patient's screening mammogram is questionable, BSGI as a "next step measure" provides critical diagnostic information without the trauma of biopsy. This new imaging technique has the potential to significantly reduce the number of invasive biopsies that result in negative findings (no cancer present) for thousands of women annually; and it can detect cancers at very early stages allowing for optimal intervention and treatment.

X-ray mammography is still the first-line screening tool for breast cancer, but it only measures differences in tissue density. BSGI is less affected by tissue density, and the metabolic information captured helps differentiate healthy from malignant tissue. So when further evaluation is needed, imaging with the Dilon 6800 helps physicians determine if suspicious findings are cancerous or not; especially in women who have dense breasts, lesions (lumps) that can be felt but not seen with mammogram or ultrasound, scar tissue or implants. The portable camera will soon be available in the areas most advanced breast imaging centers; providing rapid results at the patient's point of care.



In the largest study to date on this new medical procedure, the technology of Dilon's camera has been used to image over 500 patients at several medical institutions, many in the Hampton Roads area, including Johns Hopkins Medical Center, George Washington University Hospital, Norfolk Sentara General Hospital and Riverside Regional Medical Center in Newport News. Regional studies were obtained by the cooperative efforts of Dilon Technologies, Jefferson Laboratory and Hampton University. Medical testing is ongoing at GWU and is in its second year of a multiyear evaluation. Researchers conclude that Breast-Specific Gamma Imaging with the Dilon 6800 yields a 97% Negative Predictive Value and high sensitivity for sub-centimeter cancers, which relates to its superb ability to determine the nature of suspicious lesions (cancerous or not), and to predict when cancers are truly there. Very promising study results have been published in medical and scientific journals on this advanced imaging technology.

Combining the functional diagnostic capabilities of Breast-Specific Gamma Imaging with mammography allows for earlier detection and treatment of breast cancer. A major advantage of imaging with the Dilon 6800 is that imaging occurs at the point of care, in a women's health or breast imaging center, allowing for non-invasive same-day diagnosis.

###